Prosecution Insights
Prosecution Insights
81 pending office actions • 44 art units • 75 examiners • 1 of 81 (1%) have an AI response strategy ready • 76 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 27 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 27 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (1%) |
| §101 + other | 10 (12%) |
| §103 only | 29 (36%) |
| §102 only | 2 (2%) |
| §112 only | 11 (14%) |
| Double-patenting only | 3 (4%) |
| Double-patenting + other | 6 (7%) |
| Multi-statute (no §101) | 17 (21%) |
| No statute on record | 2 (2%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GUSTILO, ESTELLA M | 2 | 53.2% | +36.8% |
| HOANG, HAN DINH | 2 | 74.2% | +19.0% |
| CHAO, ALLEN | 2 | 66.7% | +0.0% |
| HUYNH, PHUONG N | 2 | 65.7% | +53.6% |
| BRISTOL, LYNN ANNE | 2 | 63.6% | +39.7% |
| KIM, YUNSOO | 2 | 65.8% | +34.8% |
| TAYLOR, LIA ELAN | 1 | 64.5% | +29.0% |
| WILLIS, AMANDA LYNN | 1 | 35.9% | +26.1% |
| DHOOGE, DEVIN J | 1 | 71.1% | +31.9% |
| NGUYEN, TUAN HOANG | 1 | 90.4% | +4.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18909867 | PATHOLOGICAL RESPONSE CALCULATION AND ASSESSMENT TOOL | NGUYEN, TUAN HOANG | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17378651 | ATTENTION-BASED NEURAL NETWORK TO PREDICT PEPTIDE BINDING, PRESENTATION, AND IMMUNOGENICITY | BAILEY, STEVEN WILLIAM | 396d overdue |
| 17964325 | METHOD FOR MEDIUM TREATMENT BEFORE INOCULATION | MOSS, NATALIE M | 127d overdue |
| 18523284 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | SHIAO, REI TSANG | 91d overdue |
| 17351451 | TARGETED INTEGRATION OF NUCLEIC ACIDS | GODDARD, LAURA B | 84d overdue |
| 17075238 | OVERLOAD AND ELUTE CHROMATOGRAPHY | STONEBRAKER, ALYSSA RAE | 72d overdue |
| 18315450 | SMALL PARTS CLEANING APPARATUS AND METHODS OF USE | LEE, KEVIN G | 58d overdue |
| 18627251 | BIOLOGICAL CONTEXT FOR ANALYZING WHOLE SLIDE IMAGES | ROSARIO, DENNIS | 31d overdue |
| 17473401 | TREATMENT OF CANCER WITH HER2XCD3 BISPECIFIC ANTIBODIES IN COMBINATION WITH ANTI-HER2 MAB | CHASE, CAROL ANN | 4d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18210604 | ASSEMBLY OF BISPECIFIC ANTIBODIES | HUYNH, PHUONG N | 111d overdue |
| 18124096 | PURIFICATION OF MULTISPECIFIC ANTIBODIES | BRISTOL, LYNN ANNE | 10d overdue |
| 19409123 | CELL CULTURE COMPOSITIONS AND METHODS FOR POLYPEPTIDE PRODUCTION | TAYLOR, LIA ELAN | — |
| 19145482 | SYSTEMS AND METHODS FOR HETEROGENEOUS DATA ANALYSIS | WILLIS, AMANDA LYNN | — |
| 18929474 | MACHINE LEARNING ENABLED HEPATOCELLULAR CARCINOMA MOLECULAR SUBTYPE CLASSIFICATION | DHOOGE, DEVIN J | — |
| 18799503 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR BLADDER CANCER | GUSTILO, ESTELLA M | — |
| 18416031 | Anti-Jagged1 Antibodies and Methods of Use | GUSTILO, ESTELLA M | — |
| 18516406 | DETECTING TERTIARY LYMPHOID STRUCTURES IN DIGITAL PATHOLOGY IMAGES | HOANG, HAN DINH | — |
| Art Unit | Apps |
|---|---|
| 1641 | 5 |
| 1646 | 3 |
| 1647 | 3 |
| 1622 | 3 |
| 2661 | 3 |
| 1656 | 3 |
| 1642 | 3 |
| 1643 | 3 |
| 1644 | 3 |
| 1687 | 3 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19409123 | CELL CULTURE COMPOSITIONS AND METHODS FOR POLYPEPTIDE PRODUCTION | TAYLOR, LIA ELAN | 1641 | §103§112DP | Non-Final OA | — | Pending | Dec 04, 2025 |
| 19145482 | SYSTEMS AND METHODS FOR HETEROGENEOUS DATA ANALYSIS | WILLIS, AMANDA LYNN | 2156 | §101§102§112 | Non-Final OA | — | Pending | Jul 02, 2025 |
| 18929474 | MACHINE LEARNING ENABLED HEPATOCELLULAR CARCINOMA MOLECULAR SUBTYPE CLASSIFICATION | DHOOGE, DEVIN J | — | §103 | Non-Final OA | — | Pending | Oct 28, 2024 |
| 18909867 | PATHOLOGICAL RESPONSE CALCULATION AND ASSESSMENT TOOL | NGUYEN, TUAN HOANG | — | §103 | Non-Final OA | — | Pending | Oct 08, 2024 |
| 18884545 | PREDICTING NEURODEGENERATIVE DISEASES BASED ON SPEECH ANALYSES | SERROU, ABDELALI | 2659 | §101§103 | Non-Final OA | — | Pending | Sep 13, 2024 |
| 18883384 | DEEP CONVOLUTIONAL NEURAL NETWORKS FOR TUMOR SEGMENTATION WITH POSITRON EMISSION TOMOGRAPHY | CWERN, JONATHAN | 3797 | §103Other | Final Rejection | 24d overdue | Pending | Sep 12, 2024 |
| 18846553 | DETERMINING A PATIENT’S RESPONSE TO A TREATMENT IN MULTIPLE MYELOMA | LEE, ANDREW ELDRIDGE | 3684 | §101§103 | Final Rejection | — | Pending | Sep 12, 2024 |
| 18820925 | PRODUCTION OF PROTEINS IN GLUTAMINE-FREE CELL CULTURE MEDIA | MOEHLMAN, ANDREW TERRY | 1655 | §112 | Non-Final OA | — | Pending | Aug 30, 2024 |
| 18799503 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR BLADDER CANCER | GUSTILO, ESTELLA M | 1646 | §102§103§112Other | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18793540 | GUIDED SELF-CAPTURE OF DIAGNOSTIC IMAGES | HASAN, MOHAMMED A | 2872 | §102 | Non-Final OA | — | Pending | Aug 02, 2024 |
| 18771363 | OVARIAN TOXICITY ASSESSMENT IN HISTOPATHOLOGICAL IMAGES USING DEEP LEARNING | NGUYEN, KHAI MINH | — | §103Other | Non-Final OA | — | Pending | Jul 12, 2024 |
| 18752501 | MULTI-VECTOR RECOMBINASE MEDIATED CASSETTE EXCHANGE | KONOPKA, CATHERINE ANNE | 1635 | §103§112DP | Non-Final OA | 78d overdue | Pending | Jun 24, 2024 |
| 18743859 | METHOD AND APPARATUS FOR USING OMALIZUMAB | BOUCHELLE, LAURA A | 3783 | §103 | Final Rejection | 5d overdue | Pending | Jun 14, 2024 |
| 18668774 | METHODS OF TREATING CANCER WITH PI3K INHIBITOR, GDC-0077 | BAEK, BONG-SOOK | 1611 | §103Other | Non-Final OA | — | Pending | May 20, 2024 |
| 18642305 | HIGH-THROUGHPUT METHODS FOR PREPARING LIPID NANOPARTICLES AND USES THEREOF | MITCHELL, EDWIN COLEMAN | 1619 | §102§103§112DP | Non-Final OA | — | Pending | Apr 22, 2024 |
| 18627251 | BIOLOGICAL CONTEXT FOR ANALYZING WHOLE SLIDE IMAGES | ROSARIO, DENNIS | 2676 | §101§103 | Final Rejection | 31d overdue | Pending | Apr 04, 2024 |
| 18612987 | PIPELINES FOR TUMOR IMMUNOPHENOTYPING | VARNDELL, ROSS E | 2674 | §101§102§103Other | Non-Final OA | — | Pending | Mar 21, 2024 |
| 18611567 | DATA QUALITY CONTROL AND INTEGRATION FOR DIGITAL PATHOLOGY | RAJAPUTRA, SUMAN | 2172 | §101§103 | Non-Final OA | — | Pending | Mar 20, 2024 |
| 18609758 | TIE2-BINDING AGENTS AND METHODS OF USE | ALLEN, MARIANNE P | 1647 | §112 | Non-Final OA | — | Pending | Mar 19, 2024 |
| 18587251 | METHODS OF TREATING TAU PATHOLOGIES | JUEDES, AMY E | — | §102DP | Non-Final OA | — | Pending | Feb 26, 2024 |
| 18584298 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | MOORE, SUSANNA | 1624 | §102§112 | Non-Final OA | — | Pending | Feb 22, 2024 |
| 18431838 | METHOD AND APPARATUS FOR BIOLOGICAL CELL HARVESTING | COOLEY, CHARLES E | — | §103 | Non-Final OA | — | Pending | Feb 02, 2024 |
| 18429055 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | MACFARLANE, STACEY NEE | — | DP | Non-Final OA | — | Pending | Jan 31, 2024 |
| 18417787 | BRAIN TARGETING COMPOSITIONS AND METHODS OF USE THEREOF | BUTTICE, AUDREY L | 1647 | §103§112 | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18416031 | Anti-Jagged1 Antibodies and Methods of Use | GUSTILO, ESTELLA M | — | §112DP | Non-Final OA | — | Pending | Jan 18, 2024 |
| 18413682 | FC Variants and Methods for Their Production | DEBERRY, REGINA M | — | DP | Non-Final OA | — | Pending | Jan 16, 2024 |
| 18544236 | METHODS OF TREATING CANCER USING B-RAF INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS | RODRIGUEZ, RAYNA B | 1628 | §103 | Final Rejection | — | Pending | Dec 18, 2023 |
| 18540310 | EGFR INHIBITOR AND PERK ACTIVATOR IN COMBINATION THERAPY AND THEIR USE FOR TREATING CANCER | DEKARSKE, MADELINE MCGUIRE | 1622 | §103 | Non-Final OA | — | Pending | Dec 14, 2023 |
| 18523284 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | SHIAO, REI TSANG | 1691 | §103§112 | Non-Final OA | 91d overdue | AI Ready | Nov 29, 2023 |
| 18516406 | DETECTING TERTIARY LYMPHOID STRUCTURES IN DIGITAL PATHOLOGY IMAGES | HOANG, HAN DINH | 2661 | §103 | Final Rejection | — | Pending | Nov 21, 2023 |
| 18516552 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | SCHMITT, MICHAEL J | 1629 | §103Other | Non-Final OA | 55d | Pending | Nov 21, 2023 |
| 18516417 | TUMOR IMMUNOPHENOTYPING BASED ON SPATIAL DISTRIBUTION ANALYSIS | HOANG, HAN DINH | 2661 | §103 | Final Rejection | — | Pending | Nov 21, 2023 |
| 18514280 | MODIFIED CELLS FOR THE PRODUCTION OF A RECOMBINANT PRODUCT OF INTEREST | MCKNIGHT, CIARA A | 1656 | §103§112 | Non-Final OA | — | Pending | Nov 20, 2023 |
| 18513106 | GEOGRAPHIC ATROPHY PROGRESSION PREDICTION AND DIFFERENTIAL GRADIENT ACTIVATION MAPS | GEBRESLASSIE, WINTA | 2677 | §103 | Final Rejection | — | Pending | Nov 17, 2023 |
| 18510297 | COMBINED TRANSPOSON-MEDIATED INTEGRATION AND TARGETED INTEGRATION OF NUCLEIC ACIDS INTO HOST CELLS | MEYERING, SHABANA SHABBEER | 1635 | §103§112DP | Non-Final OA | — | Pending | Nov 15, 2023 |
| 18504041 | ANTI-LY6G6D ANTIBODIES AND METHODS OF USE | MOSELEY II, NELSON B | 1642 | Other | Non-Final OA | — | Pending | Nov 07, 2023 |
| 18482237 | TREATMENT OUTCOME PREDICTION FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION USING BASELINE CHARACTERISTICS | WINDSOR, COURTNEY J | 2661 | §103 | Non-Final OA | 31d overdue | Pending | Oct 06, 2023 |
| 18377039 | Traceable Medical Vials | AFRIFA-KYEI, ANTHONY D | 2686 | §103 | Final Rejection | — | Pending | Oct 05, 2023 |
| 18464580 | ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE | SHUPE, ELIZABETH A | 1643 | §112 | Non-Final OA | 4d overdue | Pending | Sep 11, 2023 |
| 18449807 | TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING GDC-9545 AND IPATASERTIB | CHAO, ALLEN | 1622 | §103Other | Non-Final OA | 66d overdue | Pending | Aug 15, 2023 |
| 18449793 | TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING GDC-9545 AND ABEMACICLIB OR RIBOCICLIB | CHAO, ALLEN | 1622 | §103 | Final Rejection | — | Pending | Aug 15, 2023 |
| 18363155 | Multispecific Binding Protein Degrader Platform and Methods of Use | MELCHIOR, JAMES RYLAND | 1644 | §102§103§112Other | Non-Final OA | — | Pending | Aug 01, 2023 |
| 18210604 | ASSEMBLY OF BISPECIFIC ANTIBODIES | HUYNH, PHUONG N | 1641 | Other | Final Rejection | 111d overdue | Pending | Jun 15, 2023 |
| 18334531 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS | OUSPENSKI, ILIA I | 1644 | §103§112Other | Non-Final OA | 28d | Pending | Jun 14, 2023 |
| 18324406 | METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH HUMAN CYTOMEGALOVIRUS | CUNNINGCHEN, KATHLEEN MARY | 1646 | §112 | Non-Final OA | — | Pending | May 26, 2023 |
| 18201904 | METHODS FOR PREPARING MAMMALIAN CELLS FOR PERFUSION CELL CULTURE | MONTANARI, DAVID A | 1632 | §102§103 | Non-Final OA | — | Pending | May 25, 2023 |
| 18321199 | CONTAINED SINGLE-USE POWDER INDUCTION SYSTEM AND METHOD OF USE | BHATIA, ANSHU | 1774 | §103 | Non-Final OA | 27d | Pending | May 22, 2023 |
| 18319618 | Reusable Cartridges for Detecting Analytes in Solution | MONTGOMERY, ANN Y | 1678 | §112 | Non-Final OA | — | Pending | May 18, 2023 |
| 18315450 | SMALL PARTS CLEANING APPARATUS AND METHODS OF USE | LEE, KEVIN G | 1711 | §103§112 | Final Rejection | 58d overdue | Pending | May 10, 2023 |
| 18309003 | RECOMBINANT PROTEINS FOR QUANTIFICATION OF PROTEIN LEVELS | NOAKES, SUZANNE MARIE | 1656 | §112 | Non-Final OA | — | Pending | Apr 28, 2023 |
| 18194542 | HYDROXYPROPYL METHYL CELLULOSE DERIVATIVES TO STABILIZE POLYPEPTIDES | HARTLEY, MICHAEL G | 1614 | §103 | Non-Final OA | — | Pending | Mar 31, 2023 |
| 18190697 | THERMAL SEPARATOR APPARATUS FOR FLASK STIRRER AND METHOD OF USE | JARRETT, LORE RAMILLANO | 1797 | §103§112 | Final Rejection | — | Pending | Mar 27, 2023 |
| 18188168 | COMBINATION TREATMENT OF AN ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODY AND CHEMOTHERAPY | HAMA, JOANNE | 1647 | §103Other | Final Rejection | — | Pending | Mar 22, 2023 |
| 18124096 | PURIFICATION OF MULTISPECIFIC ANTIBODIES | BRISTOL, LYNN ANNE | 1643 | §112 | Final Rejection | 10d overdue | Pending | Mar 21, 2023 |
| 18043568 | HIGH THROUGHPUT, FLUORESCENCE-BASED ESTERASE ACTIVITY ASSAY FOR ASSESSING POLYSORBATE DEGRADATION RISK DURING BIOPHARMACEUTICAL DEVELOPMENT | XU, QING | 1656 | §103 | Non-Final OA | 84d | Pending | Feb 28, 2023 |
| 18174889 | METHODS FOR PRODUCING ANTIBODIES | HOWARD, ZACHARY C | 1674 | §103§112 | Non-Final OA | — | Pending | Feb 27, 2023 |
| 18173673 | POINT OF CARE DRUG DELIVERY APPARATUS AND METHOD | STIGELL, THEODORE J | 3783 | §103 | Final Rejection | — | Pending | Feb 23, 2023 |
| 18163819 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR LYMPHOMA | CASH, KAILEY ELIZABETH | 1683 | §102§103§112 | Non-Final OA | 22d | Pending | Feb 02, 2023 |
| 18058110 | PREDICTION OF PEPTIDE CLEAVAGE IN POLYPEPTIDES THROUGH PHYSICS-BASED SIMULATIONS | FONSECA LOPEZ, FRANCINI ALVARENGA | 1685 | §101§103§112 | Non-Final OA | — | Pending | Nov 22, 2022 |
| 18046865 | METHODS FOR ASSAYING T-CELL DEPENDENT BISPECIFIC ANTIBODIES | SKELDING, ZACHARY S | 1644 | DP | Final Rejection | 12d | Pending | Oct 14, 2022 |
| 17965363 | Method for Enriching Extracellular Vesicles From Biological Fluid Samples | BOESEN, CHRISTIAN C | 1684 | §102 | Non-Final OA | — | Pending | Oct 13, 2022 |
| 17964325 | METHOD FOR MEDIUM TREATMENT BEFORE INOCULATION | MOSS, NATALIE M | 1653 | §103§112 | Non-Final OA | 127d overdue | Pending | Oct 12, 2022 |
| 17822746 | EFFICIENT GENOME EDITING IN PRIMARY MYELOID CELLS | VANHORN, ABIGAIL LOUISE | 1636 | §103 | Final Rejection | 87d overdue | Pending | Aug 26, 2022 |
| 17842715 | CULTURE SYSTEM AND METHODS FOR IMPROVED MODELING OF NEUROLOGICAL CONDITIONS | TRAN, KHOA NHAT | 1632 | §103 | Final Rejection | 37d overdue | Pending | Jun 16, 2022 |
| 17783229 | ANTI-PD-L1 ANTIBODY FORMULATIONS | KIM, YUNSOO | 1641 | §103 | Final Rejection | — | Pending | Jun 07, 2022 |
| 17833719 | METHODS, SYSTEMS, AND TOOLS FOR LONGEVITY-RELATED APPLICATIONS | BEVERIDGE, CONNOR HAMMOND | 1687 | §101§103 | Non-Final OA | — | Pending | Jun 06, 2022 |
| 17587760 | PREDICTION OF SIDE-CHAIN DEGRADATION IN POLYMERS THROUGH PHYSICS BASED SIMULATIONS | LIU, GUOZHEN | 1686 | §101§103DP | Final Rejection | — | Pending | Jan 28, 2022 |
| 17629327 | DETECTING NEURALLY PROGRAMMED TUMORS USING EXPRESSION DATA | MINCHELLA, KAITLYN L | 1685 | §103 | Non-Final OA | 88d overdue | Pending | Jan 21, 2022 |
| 17643623 | QUINAZOLINYL COMPOUNDS AND METHODS OF USE | HIRAKIS, SOPHIA P | 1623 | §112 | Non-Final OA | — | Pending | Dec 10, 2021 |
| 17542138 | METHOD FOR REGENERATION OF AN OVERLOAD CHROMATOGRAPHY COLUMN | KIM, YUNSOO | 1641 | §103 | Final Rejection | — | Pending | Dec 03, 2021 |
| 17490877 | COMPOSITIONS AND METHODS FOR STABILIZING PROTEIN-CONTAINING FORMULATIONS | NGUYEN, NGOC-ANH THI | 1615 | §103 | Non-Final OA | 53d | Pending | Sep 30, 2021 |
| 17473401 | TREATMENT OF CANCER WITH HER2XCD3 BISPECIFIC ANTIBODIES IN COMBINATION WITH ANTI-HER2 MAB | CHASE, CAROL ANN | 1646 | §103§112 | Final Rejection | 4d overdue | Pending | Sep 13, 2021 |
| 17383316 | METHOD FOR THE EXPRESSION OF AN ANTIBODY-MULTIMER-FUSION | MIDDLETON, DANAYA L | 1674 | §112Other | Non-Final OA | — | Pending | Jul 22, 2021 |
| 17381145 | IMMUNOGLOBULIN A ANTIBODIES AND METHODS OF PRODUCTION AND USE | BRISTOL, LYNN ANNE | 1643 | §112 | Non-Final OA | — | Pending | Jul 20, 2021 |
| 17378651 | ATTENTION-BASED NEURAL NETWORK TO PREDICT PEPTIDE BINDING, PRESENTATION, AND IMMUNOGENICITY | BAILEY, STEVEN WILLIAM | 1687 | §101 | Final Rejection | 396d overdue | Pending | Jul 16, 2021 |
| 17351451 | TARGETED INTEGRATION OF NUCLEIC ACIDS | GODDARD, LAURA B | 1642 | §103§112Other | Non-Final OA | 84d overdue | Pending | Jun 18, 2021 |
| 17275609 | PYRIMIDINYL-HETEROARYLOXY-NAPHTHYL COMPOUNDS AND METHODS OF USE | LEE, CHIHYI NMN | 1628 | §103§112 | Final Rejection | 27d | Pending | Mar 11, 2021 |
| 17168621 | USE OF TRYPTOPHAN DERIVATIVES AND L-METHIONINE FOR PROTEIN FORMULATION | GAO, ASHLEY HARTMAN | 1678 | §103Other | Final Rejection | — | Pending | Feb 05, 2021 |
| 17075238 | OVERLOAD AND ELUTE CHROMATOGRAPHY | STONEBRAKER, ALYSSA RAE | 1642 | §103§112 | Final Rejection | 72d overdue | Pending | Oct 20, 2020 |
| 16852136 | HINGE MODIFIED ANTIBODY FRAGMENTS AND METHODS OF MAKING | HUYNH, PHUONG N | 1641 | §112 | Final Rejection | — | Pending | Apr 17, 2020 |
| 16115373 | METHODS AND SYSTEMS FOR EVALUATING TUMOR MUTATIONAL BURDEN | WOITACH, JOSEPH T | 1687 | §101§112 | Final Rejection | — | Pending | Aug 28, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial